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individual institution level to improve prevention, screening, and treat-
ment efforts.
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Background: Cell cycle checkpoint function is crucial for the preven-
tion of carcinogenesis in mammalian cells. To test the hypothesis that 
common sequence variants of genes in the cell cycle control pathway 
may affect lung cancer predisposition, we explored the associations of 
11 polymorphisms in seven cell cycle control genes with lung cancer 
risk. 
Methods: We conducted a case-control study in Caucasians that in-
cluded 1,518 lung cancer patients and 1,518 controls. 
Results: Our results showed that when individuals with at least one 
variant allele were compared to homozygous wild-type carriers, a sig-
niﬁcantly increased lung cancer risk was identiﬁed for polymorphisms 
in p53 intron 6 (rs1625895) (odds ratio [OR] = 1.29, 95% conﬁdence 
interval [CI] 1.08-1.55) and in p27 5’ untranslated region (rs34330) 
(OR = 1.27, 95% CI 1.01-1.60). Compared with the homozygous 
wild-types, the homozygous variant F31I genotype (TT) of the STK15 
gene was associated with a signiﬁcantly reduced risk for lung cancer 
(OR=0.58, 95% CI = 0.37-0.90). The AA genotype of CCND1 G870A 
was associated with a signiﬁcantly increased risk (OR = 1.26, 95% 
CI 1.03-1.53) when compared with genotypes containing at least one 
wild-type allele. In an attempt to assess the combined inﬂuence of all 
the investigated polymorphisms on lung carcinogenesis, we found that 
compared to the reference group with one variant allele, individuals 
with two (OR = 1.53, 95% CI 0.97-2.41) and three or more (OR = 1.59, 
95% CI 1.07-2.34) variant alleles exhibited increasing risk of lung 
cancer with a gene dosage effect (P for trend = 0.041). This pattern was 
more evident in ever smokers (P for trend = 0.037), heavy smokers 
(P for trend = 0.020), and older subjects (P for trend = 0.011). Higher 
order gene-gene interactions were evaluated using the classiﬁcation and 
regression tree (CART) analysis, which indicated that STK15 F31I and 
p53 intron 6 polymorphism might be associated with lung carcinogen-
esis in never/light-smokers and heavy smokers, respectively. 
Conclusions: This is the ﬁrst study using a polygenic strategy to 
elucidate the inﬂuences of a panel of cell cycle genetic polymorphisms 
on lung cancer risk. Our results suggest that cell cycle gene polymor-
phisms and smoking may function collectively to modulate the risk of 
lung cancer.
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Background: RCTs on lung cancer treatment are increasing rapidly. 
Many meta-analyses were performed to synthesize and clarify their 
results. Even if the meta-analyses represent the high level of proof, 
their quality is variable. This review attempts to identify meta-analyses 
of RCTs studying lung cancer treatment, to assess their quality and to 
identify criteria of good quality. 
Methods: A systematic research was performed using PubMed, 
EMBASE, Cochrane, Web of knowledge, and American Society of 
Clinical Oncology databases, for 1990-2006, with the following search 
terms: lung cancer, meta-analysis and systematic review. There were no 
language restrictions. Meta-analyses of RCTs on lung cancer treatment 
published as full paper were eligible. Two investigators independently 
selected the publications. When the same results were reported in 
more than one publication, the evaluation was based on a combina-
tion of all available information. Data on meta-analysis characteristics 
(publication, size, methods…) were extracted by 2 investigators. After 
a learning period, each meta-analysis was evaluated independently by 
3 reviewers using the Oxman and Guyatt index and with the scoring 
method proposed by Sacks et al. Disagreements were resolved by dis-
cussion. The clinical relevance was evaluated by 2 clinicians. Quality 
criteria were identiﬁed by discriminant analysis through 3 groups of 
meta-analyses deﬁned by their quality score (poor, middle, high). We 
also compared the reports evaluating the same intervention.
Results: A total of 1,723 articles were retrieved by the initial search. 
Fifty-nine articles were considered to be eligible for assessment. Nine 
articles corresponded to update or duplicate papers of previous publica-
tions leading to 50 distinct projects. The 50 projects reported 70 meta-
analyses. 88% of reports were published in English. The articles were 
published between 1992 and 2006, 54% after 2003. 10% of articles 
were published by authors of the Cochrane Collaboration. The median 
numbers of trials and patients per project were 11 (3-57) and 2,094 
(360-11,160) respectively. 12.5% of meta-analyses were based on in-
dividual patient data. Among the 70 meta-analyses, 76% concerned the 
non-small cell lung cancer (NSCLC), 23% the small cell lung cancer 
(SCLC) and 1% lung cancer in general. 49 meta-analyses evaluated 
chemotherapy (7 in early NSCLC, 7 in locally advanced NSCLC, 16 
in advanced NSCLC, 14 in several stages of NSCLC and 5 in differ-
ent stages of SCLC), 12 radiotherapy (1 in early NSCLC, 2 in differ-
ent stages of NSCLC, 6 in limited SCLC and 3 in different stages of 
SCLC), 2 the association of chemotherapy and radiotherapy in locally 
advanced NSCLC, 1 surgery in early NSCLC and 6 other treatments 
(immunotherapy, Chinese herbs). For 11 therapeutic questions, more 
than 2 meta-analyses were performed. Analysis on quality evaluation is 
ongoing. 
Conclusion: A large number of meta-analyses of RCTs on lung cancer 
treatment had been published in the recent years, including several on 
the same topic. Their usefulness need to be studied. The assessment 
of the quality of meta-analyses and the comparison of reports on the 
same topic could permit to help clinicians and decision-makers in their 
practice. 
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Survey evidence from ex-smokers has repeatedly afﬁrmed that person-
alised concern about health consequences is the primary motivation 
